Efficacy of adjuvant Immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials

Abstract

The benefits of immunochemotherapy employing the biological response modifier polysaccharide K (PSK) for patients with curatively resected colorectal cancer was reassessed by means of a meta-analysis of data with center randomization from 1,094 patients enrolled in three clinical trials. In all three trials, patients were followed up for at least 5 years after surgery and enrollment of the last patient and outcomes for standard chemotherapy were compared with those for chemotherapy plus PSK. The endpoints were overall survival and disease-free survival; and intent-to-treat analysis was performed without patient exclusion. Data were analyzed using the weighted average of the individual log hazard ratios. The overall survival risk ratio for all eligible patients was 0.71 (95% confidence interval (CI) : 0.55-0.90; P=0.006), and the disease-free survival risk ratio was 0.72 (95% CI: 0.58-0.90; P=0.003). The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK can improve both survival and disease-free survival of patients with curatively resected colorectal cancer.

Dietary Supplement Use in Cancer Care: Help or Harm

“…These results are confirmed by a metaanalysis of three trials (reported in 10 articles) involving 1, 094 subjects with colorectal cancer [87]. Those who took PSK showed a significant improvement in overall survival (RR 0.71; CI 0.55-0.90; P ¼ .006) and disease-free survival (RR 0.72; CI 0.58-0.90; P ¼ .003) [87]. Benefit of PSK was also demonstrated in a meta-analysis of 8,009 gastric cancer patients from eight randomized, controlled trials with an increased survival (HR 0.88; CI 0.79-0.98; P ¼ .0180) [88].…”

“…After 5 years of follow-up, the treated patient group also had a greater percentage of 5-year disease free survival (P ¼ .038) and a decreased relative risk of regional metastases (relative risk or RR 3.595; CI 1.518-8.518). These results are confirmed by a metaanalysis of three trials (reported in 10 articles) involving 1, 094 subjects with colorectal cancer [87]. Those who took PSK showed a significant improvement in overall survival (RR 0.71; CI 0.55-0.90; P ¼ .006) and disease-free survival (RR 0.72; CI 0.58-0.90; P ¼ .003) [87].…”

S3-Leitlinie – Kolorektales Karzinom

“…Es gibt eine Reihe von Publikationen zum Einsatz von Heilpilzen bei kurativ behandelten Patienten mit kolorektalem Karzinom [1309,1310]. Diese Studien stammen aus China und Japan und sind in den Originalsprachen publiziert.…”

A review of the anti-tumor effect of the combined administration of a cyclooxygenase-2 selective inhibitor and a non-specific immunostimulant protein-bound polysaccharide on an advanced colon cancer model using colon cancer cell lines

“…to have clinical effects in combined use for postoperative adjuvant chemotherapy for stomach (15,16) and colon (17)(18)(19) cancers.…”